Silence Therapeutics Reports Significant Revenue Decline and Increased R&D Expenses in Q2 2025

Silence Therapeutics plc reported a significant decline in financial performance for the second quarter of 2025, with total revenue of $224,000 for the three months ending June 30, 2025, down from $756,000 in the same period of 2024. For the first half of 2025, revenue totaled $366,000, a stark decrease from $16.5 million in the prior year. The company attributed this decline primarily to the absence of milestone payments from its collaboration with AstraZeneca, which had contributed $15 million in the previous year. The overall operating loss for the second quarter was $23.96 million, slightly higher than the $23.39 million loss reported in the same quarter of 2024.

In terms of operational changes, Silence Therapeutics has undergone a restructuring that resulted in a one-time charge of $1.32 million during the second quarter. This restructuring was part of a broader strategy to streamline operations and reduce costs. The company also reported a decrease in general and administrative expenses, which fell to $5.13 million from $7.01 million year-over-year, reflecting efforts to cut administrative costs amid changing compliance requirements.

The company’s research and development (R&D) expenses increased significantly, totaling $17.65 million for the second quarter, compared to $13.80 million in the same period last year. This increase was driven by advancements in its proprietary programs, particularly the Phase 2 clinical trial for divesiran, and preparations for the Phase 3 trial of zerlasiran. As of June 30, 2025, Silence Therapeutics had cash and cash equivalents of $41.74 million, down from $121.33 million at the end of 2024, indicating a need for future funding to support ongoing R&D activities.

Silence Therapeutics continues to focus on its clinical pipeline, which includes divesiran and zerlasiran, both of which are in advanced stages of development. The company has reported progress in its clinical trials, with divesiran showing promising results in reducing hematocrit levels in patients with polycythemia vera. The company is also engaged in discussions for potential partnerships to advance the development of zerlasiran. Looking ahead, Silence Therapeutics anticipates continued operating losses as it invests in its R&D efforts, with plans to seek additional funding through equity offerings and collaborations to sustain its operations and clinical programs.